VIDEO: Practice-changing approvals in psoriatic arthritis

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

We have two recent approvals in psoriatic arthritis. These are an interleukin-23 inhibitor risankizumab and JAK inhibitor upadacitinib. They both are not new mechanisms of action, but they are additional options in the known classes of medications that we have to treat psoriatic arthritis. A little bit further in the pipeline, I think we're all excited about bimekizumab, which is an IL-17 A and F inhibitor. Its application was accepted by the FDA for review for psoriasis. And the phase three clinical trials in psoriatic arthritis are completing, so we're looking forward to that as well.

Dr. Orbai, I think this is so exciting that we can take drugs that we have been using in our other diseases in rheumatology, and then moving them along the pipeline to include other diseases. So, for example, we have all been using JAK inhibitors for rheumatoid arthritis now for several years. And now it's exciting to see that it is just being approved for psoriatic arthritis.

I fully agree. And I think we're learning from you every day, from the experience in rheumatoid arthritis, with a new safety trial that was done in the rheumatoid arthritis population. So I think we very much draw on that experience.